Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392648 | 0.93 | USP2 (0.56) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17149731 | 0.86 | HPGD (0.46) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8803621 | 0.82 | USP2 (0.49) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5053 | 0.81 | HPGD (0.68) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL861278 | 0.81 | USP2 (0.64) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7858182 | 0.81 | HPGD (0.68) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13812233 | 0.80 | HPGD (0.71) | HPGDUSP2SMN1; SMN2KMT2AEPHX1 | |
| SCHEMBL18432213 | 0.79 | HPGD (0.71) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL16612394 | 0.79 | USP2 (0.62) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21707988 | 0.79 | HPGD (0.71) | HPGDUSP2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | HPGD 987/4885USP2 2291/4885SMN1; SMN2 4785/4885 |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | HPGD 861/4885USP2 4544/4885SMN1; SMN2 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.